Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Gross PP&E Adjustments (2016 - 2025)

Arrowhead Pharmaceuticals' Other Gross PP&E Adjustments history spans 16 years, with the latest figure at $420.9 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 4.64% year-over-year to $420.9 million; the TTM value through Dec 2025 reached $420.9 million, up 4.64%, while the annual FY2025 figure was $416.8 million, 5.05% up from the prior year.
  • Other Gross PP&E Adjustments reached $420.9 million in Q4 2025 per ARWR's latest filing, up from $416.8 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $420.9 million in Q4 2025 to a low of $5.2 million in Q2 2022.
  • Average Other Gross PP&E Adjustments over 5 years is $198.3 million, with a median of $86.3 million recorded in 2023.
  • Peak YoY movement for Other Gross PP&E Adjustments: plummeted 79.17% in 2022, then surged 933.69% in 2023.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $28.9 million in 2021, then skyrocketed by 62.15% to $46.8 million in 2022, then surged by 612.55% to $333.8 million in 2023, then increased by 20.49% to $402.2 million in 2024, then increased by 4.64% to $420.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Other Gross PP&E Adjustments are $420.9 million (Q4 2025), $416.8 million (Q3 2025), and $410.8 million (Q2 2025).